Combination Treatments and Compositions for Wound Healing

Abstract

Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.

We claim: 
     
         1 . A method selected from the group consisting of (a) a method of treating a subject having a wound not healing at an expected rate, which comprises administration of an effective amount of a viral VEGF and a viral anti-inflammatory cytokine to the wound, (b) method of treatment comprising administering to a subject in need thereof a composition comprising therapeutically effective amounts of a viral VEGF and a viral anti-inflammatory cytokine to the wound, wherein optionally said viral VEGF and a viral anti-inflammatory cytokine are administered in combination or administered separately, optionally at about the same time or sequentially (c) a method comprising administration of an effective amount of each of (i) VEGF, optionally a viral VEGF, optionally a parapoxvirus VEGF-E, optionally orf virus VEGF-E, and (ii) an anti-inflammatory cytokine, optionally a viral anti-inflammatory cytokine, optionally a viral anti-inflammatory interleukin, optionally viral IL-10, to a subject in need of treatment therewith, and (d). 
     
     
         2 . A method according to  claim 1 , wherein said viral VEGF is VEGF-E, wherein the VEGF-E optionally is a parapoxvirus virus VEGF-E. 
     
     
         3 . A method according to  claim 1 , wherein said viral anti-inflammatory cytokine is a viral anti-inflammatory interleukin, optionally viral IL-10, optionally parapoxvirus IL-10, optionally orf virus IL-10. 
     
     
         4 . A method according to  claim 1 , wherein the subject suffers from a wound selected from the group consisting of an acute wound, a delayed-healing wound, an incompletely healing wound, a chronic wound (optionally a diabetic ulcer, a venous ulcer, a pressure ulcer, a vasculitic ulcer, or an arterial ulcer), and a dehiscent wound, and wherein the composition optionally is applied prior to repair or closure of a wound. 
     
     
         5 . A composition comprising a viral VEGF and a viral anti-inflammatory cytokine effective to promote wound healing and a pharmaceutally acceptable carrier, wherein composition optionally is formulated for administration via a route selected from the group consisting of topical administration and injection. 
     
     
         6 . A composition according to  claim 5  which is in the form of a cream, ointment, gel, emulsion, lotion, foam, or paint, wherein when the composition is a gel, the gel optionally comprises a nonionic polyoxyethylene-polyoxypropylene copolymer gel. 
     
     
         7 . A composition according to  claim 5 , wherein said viral VEGF is VEGF-E, wherein the VEGF-E optionally is a parapoxvirus virus VEGF-E. 
     
     
         8 . A composition according to  claim 5 , wherein said viral anti-inflammatory cytokine is a viral anti-inflammatory interleukin, optionally viral IL-10, optionally parapoxvirus IL-10, optionally orf virus IL-10. 
     
     
         9 . A method of manufacture of a medicament comprising bringing together in a single or separate vessels amounts of a viral VEGF and a viral anti-inflammatory cytokine effective to promote wound healing and a pharmaceutically acceptable carrier. 
     
     
         10 . A method according to  claim 9 , wherein said viral VEGF is VEGF-E, wherein the VEGF-E optionally is a parapoxvirus virus VEGF-E. 
     
     
         11 . A method according to  claim 9 , wherein said viral anti-inflammatory cytokine is a viral anti-inflammatory interleukin, optionally viral IL-10, optionally parapoxvirus IL-10, optionally orf virus IL-10. 
     
     
         12 . An article of manufacture comprising package material containing therapeutically effective amounts of a viral VEGF and a viral anti-inflammatory cytokine together with instructions for use in the treatment of a wound in or on a subject. 
     
     
         13 . An article of manufacture according to  claim 12 , wherein the viral VEGF and the viral anti-inflammatory cytokine are contained in a single vessel. 
     
     
         14 . An article of manufacture according to  claim 12 , wherein the viral VEGF and the viral anti-inflammatory cytokine are contained in separate vessels. 
     
     
         15 . An article of manufacture according to  claim 12 , wherein said viral VEGF is VEGF-E, wherein the VEGF-E optionally is a parapoxvirus virus VEGF-E. 
     
     
         16 . An article of manufacture according to  claim 12 , wherein said viral anti-inflammatory cytokine is a viral anti-inflammatory interleukin, optionally viral IL-10, optionally parapoxvirus IL-10, optionally orf virus IL-10. 
     
     
         17 . An article of manufacture according to  claim 12 , wherein the subject suffers from a wound selected from the group consisting of an acute wound, a delayed-healing wound, an incompletely healing wound, a chronic wound (optionally a diabetic ulcer, a venous ulcer, a pressure ulcer, a vasculitic ulcer, or an arterial ulcer), and a dehiscent wound, and wherein the composition optionally is applied prior to repair or closure of a wound. 
     
     
         18 . An article of manufacture according to  claim 12 , wherein the viral VEGF and the viral anti-inflammatory cytokine are (a) formulated for administration by injection or (b) formulated for topical administration. 
     
     
         19 . An article comprising package material containing therapeutically effective amounts of each of (i) VEGF, optionally a viral VEGF, optionally a parapoxvirus VEGF-E, optionally orf virus VEGF-E, and (ii) an anti-inflammatory cytokine, optionally a viral anti-inflammatory cytokine, optionally a viral anti-inflammatory interleukin, optionally viral IL-10, together with instructions for use in the treatment of a wound in or on a subject.